Anne Cropp, PharmD, is Chief Scientific Officer of Early Access Care LLC, a health care company focused on facilitating all stakeholders involved in the review and approval of Expanded Access and Compassionate Use requests for investigational drugs.
Prior to founding Early Access Care, Cropp was Vice President in the Global Product Development Group at Pfizer Inc. She has 25 years of experience in the biopharmaceutical industry, marked by achievements in innovation and successful development of new drug products. As an innovator, Cropp has held a number of global leadership positions in R&D and has led matrixed development teams from Phase 1 through NDA/MAA submission and successful registration and commercialization. Her expertise in drug development spans Phases 1-4, both large and small molecules. She has expertise in planning and executing drug development programs for compounds with multiple routes of administration, including oral, intravenous, subcutaneous and inhalation, as well as devices for inhalation and injection.
Cropp has been responsible for the strategic planning, development and execution of investigational drugs across a wide spectrum of disease areas in adult and pediatric patients. She has developed and executed very large and mid-sized programs in disease areas that span Alzheimer’s disease, heart failure, hypercholesterolemia, hypertension, type I and II diabetes mellitus and vascular surgery.
Cropp served as Chair of the Pfizer Pediatric Council for eight years, and she advised pan-therapeutic area teams on issues related to planning for regulatory meetings, pediatric protocols, and execution of pediatric clinical trials.